Login to Your Account

Senate user fee bill would change rules for clinical studies

By Mark McCarty
Regulatory Editor

Thursday, May 11, 2017

The FDA user fee bill passed a Senate committee vote with a hefty 21-2 margin without a provision for drug reimportation, but the bill does include an amendment that would require that clinical trials both broaden access and enroll a body of patients that reflects the populations that would receive that therapeutic product.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription